Ananym Capital Management LP Buys 59,960 Shares of Henry Schein, Inc. $HSIC

Ananym Capital Management LP boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 12.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 547,156 shares of the company’s stock after acquiring an additional 59,960 shares during the period. Henry Schein comprises approximately 14.0% of Ananym Capital Management LP’s portfolio, making the stock its 3rd largest position. Ananym Capital Management LP’s holdings in Henry Schein were worth $36,315,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HSIC. CYBER HORNET ETFs LLC purchased a new position in shares of Henry Schein during the second quarter worth about $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the 2nd quarter valued at about $27,000. Sentry Investment Management LLC boosted its position in shares of Henry Schein by 132.1% in the 3rd quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after purchasing an additional 515 shares during the period. Evelyn Partners Investment Management Services Ltd acquired a new stake in shares of Henry Schein in the 2nd quarter valued at about $62,000. Finally, Mather Group LLC. purchased a new position in Henry Schein during the 3rd quarter worth approximately $71,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Up 0.8%

Henry Schein stock opened at $75.57 on Friday. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $89.29. The stock has a 50 day moving average of $78.21 and a two-hundred day moving average of $72.86. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $8.67 billion, a price-to-earnings ratio of 23.11, a PEG ratio of 2.24 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same period last year, the business posted $1.19 EPS. The company’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

HSIC has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price target on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Mizuho lifted their target price on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. UBS Group upped their price target on shares of Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Finally, Wells Fargo & Company increased their price target on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Henry Schein presently has a consensus rating of “Hold” and an average target price of $85.58.

Insider Activity

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total value of $224,562.24. Following the transaction, the director directly owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Stanley M. Bergman sold 43,812 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the transaction, the chief executive officer owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. The trade was a 10.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 104,556 shares of company stock valued at $8,476,351. Corporate insiders own 1.08% of the company’s stock.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.